A Phase 2/3 interventional study of Dexmedetomidine and Midazolam in Anesthesia, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 4 sites in United States. Open to participants aged 28 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2017-08-23.
Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to characterize the safety, and efficacy of Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a continuous IV infusion in preterm subjects, ages ≥ 28 weeks through \< 36 weeks gestational age.
Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.
First submitted before Hospira became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age: subjects must fit the following age range at screening:
Preterm subjects ≥28 weeks through \<36 weeks, gestational age;
Note: Gestational age (in weeks) will be calculated as follows: the time elapsed between the first day of the last menstrual period and the day of enrollment.
Exclusion Criteria:
Neonate subjects with neurological conditions that prohibit an evaluation of sedation such as:
Subjects with second degree or third degree heart block unless subject has a pacemaker or pacing wires are in situ.
Note: If subject's status-post Cardio Pulmonary Bypass (CPB) was managed without pacing wires in situ, the subject must not be suspected to be in second degree or third degree heart block at the time of DEX administration.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
Drug: Dexmedetomidine · Drug: Midazolam · Drug: Fentanyl · Drug: Morphine
Percent of Subjects Requiring Rescue Midazolam for Sedation
Time frame: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).
Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion
Time frame: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).
Amount of Rescue Medication (Midazolam) for Sedation During Dexmedetomidine Infusion
Time frame: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).
Amount of Rescue Medication for Analgesia During DEX Infusion
Time frame: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).
Time Spent With a Total N-PASS Score >3 During DEX Infusion
The N-PASS score \>3 indicates adequately sedated and not manifesting signs of pain/agitation.
Time frame: Predose, loading dose (LD) 5 & 10mins/if LD is 20mins (5, 10, 15 & 20mins); maintenance infusion: 0 min, every 15mins (1st hr); every 30mins (2hrs), then hourly; within 5mins of DEX discontinuation; 5mins pre and post rescue medication
Time to Successful Extubation
Time frame: From the start of study drug infusion to the study completion/withdrawal (Approximately 48 hours)
Neonatal subjects enrolled from 3 centers in the United States
| Milestone | Dexmedetomidine |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
| percentage of participants | Dexmedetomidine |
|---|---|
| Percent of Subjects Requiring Rescue Midazolam for Sedation | 0 |
| participant | Dexmedetomidine |
|---|---|
| Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion | 1 |
No measurements were reported for this outcome.
| mcg/kg | Dexmedetomidine |
|---|---|
| Amount of Rescue Medication for Analgesia During DEX Infusion | 1 |
The N-PASS score \>3 indicates adequately sedated and not manifesting signs of pain/agitation.
| Hours | Dexmedetomidine |
|---|---|
| Time Spent With a Total N-PASS Score >3 During DEX Infusion | 0.44 ± 0.769 |
| Hours | Dexmedetomidine |
|---|---|
| Time to Successful Extubation | 37.3 (23.083 to 97.833) |
Collected over Treatment Emergent Adverse Events. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexmedetomidine | — | 0/6 (0%) | 3/6 (50%) |
| Event | Dexmedetomidine |
|---|---|
| Umbilcal herniaGastrointestinal disorders | 1/6 |
| HypernatraeniaMetabolism and nutrition disorders | 1/6 |
| BlisterSkin and subcutaneous tissue disorders | 1/6 |
All subjects that received study drug.
| Age, Categorical(Participants) | Dexmedetomidine |
|---|---|
| <=18 years | 6 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(weeks) | Dexmedetomidine |
|---|---|
| Age Continuous | 0.8 ± 1.36 |
| Age Continuous: units: Gestational Age | 32.5 ± 2.74 |
| Sex: Female, Male(Participants) | Dexmedetomidine |
|---|---|
| Female | 4 |
| Male | 2 |
| Region of Enrollment(participants) | Dexmedetomidine |
|---|---|
| United States | 6 |
The record gives a start of Mar 2012, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Hospira, now a wholly owned subsidiary of Pfizer →